Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FVT

RubrYc Therapeutics Presents at the New York Venture Summit


SAN RAMON, Calif., July 10, 2018 /PRNewswire/ -- RubrYc Therapeutics, Inc., a biotherapeutics discovery business, announced today it was selected as a presenting company at the New York Venture Summit, held July 10-11 in New York City. 

RubrYc Therapeutics, Inc. (PRNewsfoto/RubrYc Therapeutics, Inc.)

"I am delighted that RubrYc Therapeutics was chosen to present at the New York Venture Summit and will use this forum to disclose recent results that demonstrate the power of our platform technology to drive and monitor immune responses to desired epitopes," said Dr. Isaac Bright, CEO of RubrYc Therapeutics. "These data further validate the utility of our antibody discovery platform to identify high-value therapeutic candidates in a time efficient manner."

RubrYc Therapeutics is focused on improving drug discovery through proprietary insights into critical interactions at the drug/target interface. Using diverse chemical libraries developed and supplied by HealthTell, Inc., RubrYc is training algorithms that inform improved decision-making throughout drug discovery. The company collaborates with biotechnology companies in early drug discovery and develops its own pipeline of therapeutic antibodies. 

"The data presented at the New York Venture Summit represent the next phase of development of our antibody discovery platform.  We are harnessing this capability to advance our internal programs and to the advantage of our partner companies," said Dr. Matthew Greving Ph.D., Co-founder and VP of Technology at RubrYc Therapeutics.

About RubrYc Therapeutics

Founded in 2017, RubrYc Therapeutics, Inc. emerged as a biotherapeutic discovery partner of immunomics leader HealthTell, Inc.  The Company has exclusive rights to HealthTell technology and combines binding information from diverse chemical library assays, with gold-standard drug discovery methods to develop biotherapeutic candidates that are optimized for clinical development. 

Contact:

Isaac J. Bright, MD
CEO
RubrYc Therapeutics, Inc.
2420 Camino Ramon
Suite 125
San Ramon, CA  94583
[email protected]

 

SOURCE RubrYc Therapeutics, Inc.


These press releases may also interest you

at 12:30
ApolloMD has announced today that it is a 2024 Top Workplaces Culture Excellence winner by Energage, a purpose-driven organization that develops solutions to build and brand Top Workplaces. The Top Workplaces program has a 17-year history of...

at 12:30
Watercrest Senior Living Group proudly announces the promotion of James Brassard to a new executive leadership role as Director of Market Street Operations. Market Street Memory Care Residences are luxury communities purposefully designed and...

at 12:22
Claudia Black, PhD, and Meadows Behavioral Healthcare are proud to announce the release of Undaunted Hope, featuring a foreword by Bessel van der Kolk, MD, author of the New York Times bestseller The Body Keeps the Score....

at 12:20
The "Elastomers: Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering. The Global Elastomers Market was valued at USD 105 Billion in 2023 and is expected to grow to USD 153.5 Billion in 2028, rising at a CAGR...

at 12:07
Getlabs, the nationwide leader in at-home diagnostics collection, has joined forces with Inocras, a leading AI-driven whole genome testing company that empowers patients with critical genetic insights for cancer and rare diseases....

at 12:06
Elegancia Healthcare W.L.L, a subsidiary of Estithmar Holding has entered into a second strategic agreement with...



News published on and distributed by: